RxDoctor Payments Data

Julie Tobak, MD

Gastroenterology · Scarsdale, NYNPI 1679506034

Payments from drug & device makers

$15,820in general payments, 2019–2025

Across 118 payments — averaging $134.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$12K
  • Olympus Medical Systems Corporation$1K
  • Echosens North America, Inc.$627
  • E.r. Squibb & Sons, L.L.C.$314
  • Pfizer$245
  • AbbVie$216
  • plus $947 from 14 others

What the payments were for

  • Consulting fees$7205%
  • Speaking & faculty fees$9,89063%
  • Travel & lodging$2,25114%
  • Food & beverage$2,95419%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,820 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$109,983
Medicare patients
264
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin15$32,748
CreonLipase/Protease/Amylase13$28,560
LinzessLinaclotide23$21,892
MotegrityPrucalopride Succinate16$16,307
Dexlansoprazole DrDexlansoprazole49$14,148
VoqueznaVonoprazan Fumarate13$12,716
Mesalamine13$6,738
ClenpiqSod Picosulf/Mag Ox/Citric Ac29$4,870
Ursodiol12$3,481
Famotidine159$2,600
Esomeprazole Magnesium22$2,265
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,060
Pantoprazole Sodium126$1,837
Lansoprazole12$1,190
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates17$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$216$50,45236 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$177$32,74815 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$49$16,30716 claims
Phathom Pharmaceuticals, Inc.Voquezna$12,272$12,71613 claims
Ferring Pharmaceuticals Inc.Clenpiq$47$4,87029 claims
Braintree Laboratories, Inc.Sutab$29$2,06013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Scarsdale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →